Concepedia

S. Klawitter

SK

Statistics

Publications

3

Citations

34

H-Index

3

Active since

2016

Affiliations

Roche Pharma AG (Germany)(Current)

S. Klawitter is an author at Roche Pharma AG (Germany) specializing in cancer therapeutics, ovarian cancer, and medicine.

ORCID

Top concepts

Publications per year

2016–2024

3

Publications

3

Cluster analysis of long COVID symptoms for deciphering a syndrome and its long-term consequence

Jacqueline Niewolik, Marie Mikuteit, S. Klawitter et al. · Immunologic Research · 2024 · 13 citations · Full text

Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group

Alexander Mustea, Pauline Wimberger, G. Oskay‐Oezcelik et al. · Annals of Oncology · 2016 · 11 citations · Full text

, , +6

First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.

Andreas Schneeweiß, Frank Förster, Hans Tesch et al. · PubMed · 2016 · 10 citations

1–3 of 3